Early effects of imatinib mesylate on the expression of insulin-like growth factor binding protein-3 and positron emission tomography in patients with gastrointestinal stromal tumor

Cancer

Volumn 107, Issue 8, 2006, Pages 1898-1908

  Trent, Jonathan C ^a   Ramdas, Latha ^a   Dupart, Jheri ^a   Hunt, Kelly ^a   Macapinlac, Homer ^a   Taylor, Ellen ^a   Hu, Limei ^a   Salvado, August ^b   Abbruzzese, James L ^a   Pollock, Raphael ^a   Benjamin, Robert S ^a   Zhang, Wei ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Gastrointestinal stromal tumor; Gene expression; Imatinib mesylate; Insulin like growth factor binding protein 3; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IMATINIB; MESSENGER RNA; SOMATOMEDIN BINDING PROTEIN 3;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL VIABILITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA MICROARRAY; DOWN REGULATION; DRUG EFFICACY; GASTROINTESTINAL STROMAL TUMOR; GENE CLUSTER; GENE EXPRESSION; HUMAN; HUMAN CELL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN INDUCTION; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; SARCOMA CELL; SIGNAL TRANSDUCTION; VALIDATION PROCESS; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL SURVIVAL; GASTROINTESTINAL STROMAL TUMORS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; PYRIMIDINES; SARCOMA; UP-REGULATION;

EID: 33750076675     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22214     Document Type: Article

References (36)

1. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Int J Surg Pathol. 2002;10:81-89.
2. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231:51-58.
3. Nilsson B, Beumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in western Sweden. Cancer. 2005;103:821-829.
4. Trent JC, Beach J, Burgess MA, et al. A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. Cancer. 2003;98:2693-2699.
5. Patel S, Vadhan-Raj S, Papadopoulos N, et al. High-dose Ifosfamide in bone and soft-tissue sarcomas - results of phase II and pilot studies -dose response and schedule dependence. J Clin Oncol. 1997;15:2378-2384.
6. Patel S, Vadhan-Raj S, Burgess M, et al. Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol. 1998;21:317-321.
7. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472-480.
8. Rankin C, von Mehren M, Blanke CD, et al. Dose effect of imatinib (IM) in patients (pts) with metastatic GIST - Phase III Sarcoma Group Study S0033. Am Soc Clin Oncol. 2004;23:815. Abstract 9005.
9. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364:1127-1134.
10. Van den Abbeele A, Badawi R, Cliche J-P, et al. 18F-FDG PET predicts response to imatinib mesylate (Gleevec) in patients with advanced gastrointestinal stromal tumors (GIST). Proc Am Soc Clin Oncol. 2002;21:403a. Abstract 1610.
11. Choi H, Charnsangavej C, de Castro Faria S, et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol. 2004;183:1619-1628.
12. Choi H, Charnsangavej C, Macapinlac H, et al. Correlation of computerized tomography (CT) and proton emission tomography (PET) in patients with metastatic GIST treated at a single institution with imatinib mesylate. Am Soc Clin Oncol. 2003;22:819. Abstract 3290.
13. Blay JY, Bonvalot S, Casali P, et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol. 2005;16:566-578.
14. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363:1346-1353.
15. Schedlich LJ, Graham LD. Role of insulin-like growth factor binding protein-3 in breast cancer cell growth. Microsc Res Tech. 2002;59:12-22.
16. Schedlich LJ, O'Han MK, Leong GM, Baxter RC. Insulin-like growth factor binding protein-3 prevents retinoid receptor heterodimerization: implications for retinoic acid-sensitivity in human breast cancer cells. Biochem Biophys Res Commun. 2004;314:83-88.
17. Tuveson DA, Willis NA, Jacks T, et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene. 2001;20:5054-5058.
18. Wang G, Kong H, Sun Y, et al. Genome-wide analysis of the cyclin family in Arabidopsis and comparative phylogenetic analysis of plant cyclin-like proteins. Plant Physiol. 2004;135:1084-1099.
19. Shmulevich I, Hunt K, El-Naggar A, et al. Tumor specific gene expression profiles in human leiomyosarcoma: an evaluation of intratumor heterogeneity. Cancer. 2002;94:2069-2075.
20. Baggerly KA, Coombes KR, Hess KR, et al. Identifying differentially expressed genes in cDNA microarray experiments. J Comput Biol. 2001;8:639-659.
21. Trent JC 2nd, McConkey DJ, Loughlin SM, Harbison MT, Fernandez A, Ananthaswamy HN. Ras signaling in tumor necrosis factor-induced apoptosis. EMBO J. 1996;15:4497-4505.
22. Hutchings M, Mikhaeel NG, Fields PA, Nunan T, Timothy AR. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol. 2005;16:1160-1168.
23. Naumann R, Vaic A, Beuthien-Baumann B, et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol. 2001;115:793-800.
24. Swisher SG, Maish M, Erasmus JJ, et al. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thoracic Surg. 2004;78:1152-1160; discussion 1152-1160.
25. Kazama T, Faria SC, Varavithya V, Phongkitkarun S, Ito H, Macapinlac HA. FDG PET in the evaluation of treatment for lymphoma: clinical usefulness and pitfalls. Radiographics. 2005;25:191-207.
26. Wang W, Macapinlac H, Larson SM, et al. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab. 1999;84:2291-2302.
27. Subramanian S, West RB, Corless CL, et al. Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles. Oncogene. 2004;23:7780-7790.
28. Frolov A, Chahwan S, Ochs M, et al. Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors. Mol Cancer Ther. 2003;2:699-709.
29. Baxter RC, Butt AJ, Schedlich LJ, Martin JL. Antiproliferative and pro-apoptotic activities of insulin-like growth factor-binding protein-3. Growth Horm IGF Res. 2000;10:S10-11.
30. Brodt P, Samani A, Navab R. Inhibition of the type I insulin-like growth factor receptor expression and signaling: novel strategies for antimetastatic therapy. Biochem Pharmacol. 2000;60:1101-1107.
31. Mauro L, Salerno M, Morelli C, Boterberg T, Bracke ME, Surmacz E. Role of the IGF-I receptor in the regulation of cell-cell adhesion: implications in cancer development and progression. J Cell Physiol. 2003;194:108-116.
32. Zhang D, Brodt P. Type 1 insulin-like growth factor regulates MT1-MMP synthesis and tumor invasion via PI 3-kinase/Akt signaling. Oncogene. 2003;22:974-982.
33. Camirand A, Pollak M. Co-targeting IGF-1R and c-kit: synergistic inhibition of proliferation and induction of apoptosis in H 209 small cell lung cancer cells. Br J Cancer. 2004;90:1825-1829.
34. Lee HY, Moon H, Chun KH, et al. Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells. J Natl Cancer Inst. 2004;96:1536-1548.
35. Oesterreicher S, Blum WF, Schmidt B, Braulke T, Keubler B. Interaction of insulin-like growth factor II (IGF-II) with multiple plasma proteins: high affinity binding of plasminogen to IGF-II and IGF-binding protein-3. J Biol Chem. 2005;280:9994-10000.
36. Sebastian S, Kenkare UW. Stimulation of brain hexokinase gene expression by recombinant brain insulin-like growth factor in C6 glial cells. Exp Cell Res. 1999;246:243-247.